| New chemotherapy combinations for advanced bladder cancer. | |
| | |
MedLine Citation:
|
PMID: 11493774 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Transitional cell carcinoma of the urothelium is considered a chemosensitive malignancy. Until recently, the methotrexate, vinblastine, doxorubicin and cisplatin combination has been considered the standard for treating this disease. The development of new chemotherapeutic agents such as gemcitabine and the taxanes has opened up promising new perspectives in the treatment of this disease. However, the preliminary phase II data must be confirmed in adequately conducted phase III trials. |
| | |
Authors:
|
J Bellmunt; S Albiol |
Related Documents
:
|
15813504 - Gemcitabine and cisplatin in advanced nasopharyngeal carcinoma: a pilot study. 17966214 - Feasibility and efficacy of chemotherapy with gemcitabine mono and with paclitaxel/mito... 11368414 - Phase ii study of weekly gemcitabine in patients with metastatic breast cancer relapsin... 9728584 - Gemcitabine and paclitaxel combinations in non-small cell lung cancer. 3607724 - Malignant rhabdoid tumor of the extremity. 216854 - Selective surgical resection in small cell carcinoma of the lung. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current opinion in urology Volume: 11 ISSN: 0963-0643 ISO Abbreviation: Curr Opin Urol Publication Date: 2001 Sep |
Date Detail:
|
Created Date: 2001-08-08 Completed Date: 2001-10-11 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9200621 Medline TA: Curr Opin Urol Country: United States |
Other Details:
|
Languages: eng Pagination: 517-22 Citation Subset: IM |
Affiliation:
|
Medical Oncology Service, General University Vall d'Hebron Hospital, Barcelona, Spain. bellmunt@hg.vhebron.es |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Combined Chemotherapy Protocols*
/
therapeutic use* Bridged Compounds / administration & dosage Carcinoma, Transitional Cell / drug therapy*, mortality, pathology* Cisplatin* Clinical Trials as Topic Deoxycytidine / administration & dosage, analogs & derivatives Dose-Response Relationship, Drug Doxorubicin* Drug Combinations Female Humans Male Methotrexate* Neoplasm Metastasis Platinum / administration & dosage Prognosis Severity of Illness Index Survival Analysis Taxoids* Urinary Bladder Neoplasms / drug therapy*, mortality, pathology* Vinblastine* |
| Chemical | |
Reg. No./Substance:
|
0/Bridged Compounds; 0/Drug Combinations; 0/M-VAC protocol; 0/Taxoids; 103882-84-4/gemcitabine; 15663-27-1/Cisplatin; 1605-68-1/taxane; 23214-92-8/Doxorubicin; 59-05-2/Methotrexate; 7440-06-4/Platinum; 865-21-4/Vinblastine; 951-77-9/Deoxycytidine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Recent clinical trials in superficial bladder cancer.
Next Document: Second-line treatment of advanced transitional cell carcinoma of the urothelial tract.